Wyss Institute’s organs-on-chips develops into new company
In order to accelerate the development of new pharmaceuticals, Harvard’s Wyss Institute for Biologically Inspired Engineering announced that its human organs-on-chips technology will be commercialized by a newly formed private company. The announcement on Monday followed a worldwide license agreement between Harvard’s Office of Technology Development (OTD) and the startup Emulate Inc. The agreement, relating to the use of the institute’s automated human organs-on-chips platform, includes not only pharmaceuticals, but chemical, cosmetic, and personalized medicine products as well. “This is a big win towards achieving our institute’s mission of transforming medicine and the environment by developing breakthrough technologies and facilitating their translation from the benchtop to the marketplace,” said Wyss Institute Director Donald Ingber, who led the organs-on-chips effort. Credit: Harvard’s...